Company to Also Detail SY-1365 Phase 1 Clinical Trial Design
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 2 clinical trial of SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the European Society of Medical Oncology (ESMO) 2017 Congress taking place September 8-12 in Madrid, Spain. The Company will also present on the design of its Phase 1 clinical trial for SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors.
Details on the presentations are as follows:
Date & Time: Saturday, September 9, from 1:15 – 2:15 p.m. CEST (7:15
-8:15 a.m. EDT)
Presentation Title: Pharmacodynamic and
pharmacokinetic evaluation of SY-1425 (tamibarotene) in
biomarker-selected acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS) patients
Session Title: Haematological Malignancies
Presenter:
Emmanuelle di Tomaso, Ph.D., Vice President, Translational Medicine,
Syros
Abstract Number: 1032P
Location: IFEMA - Feria de
Madrid, Poster area (Hall 8)
Date & Time: Monday, September 11, from 1:15 – 2:15 p.m. CEST (7:15
-8:15 a.m. EDT)
Presentation Title: A Phase 1 Study of SY-1365, a
Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors
Session
Title: Developmental Therapeutics
Presenter: Emmanuelle di Tomaso,
Ph.D., Vice President, Translational Medicine, Syros
Abstract
Number: 425TiP
Location: IFEMA - Feria de Madrid, Poster area (Hall
8)
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor in a Phase 1 clinical trial for patients with advanced solid
tumors, including transcriptionally dependent cancers such as triple
negative breast, small cell lung and ovarian cancers. Led by a team with
deep experience in drug discovery, development and commercialization,
Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the clinical utility of Syros’ drug
candidates, including SY-1425 and SY-1365, and the benefits of Syros’
gene control platform. The words ‘‘anticipate,’’ ‘‘believe,’’
‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’
‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’
‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various important
factors, including: Syros’ ability to: advance the development of its
programs under the timelines it projects in current and future clinical
trials; demonstrate in any current and future clinical trials the
requisite safety, efficacy and combinability of its drug candidates;
replicate scientific and non-clinical data in clinical trials;
successfully develop a companion diagnostic test to identify patients
with biomarkers associated with the RARA super-enhancer; obtain
and maintain patent protection for its drug candidates and the freedom
to operate under third party intellectual property; obtain and maintain
necessary regulatory approvals; identify, enter into and maintain
collaboration agreements with third parties; manage competition; manage
expenses; raise the substantial additional capital needed to achieve its
business objectives; attract and retain qualified personnel; and
successfully execute on its business strategies; risks described under
the caption “Risk Factors” in Syros’ Quarterly Report on Form 10-Q for
the quarter ended June 30, 2017, which is on file with the Securities
and Exchange Commission; and risks described in other filings that Syros
makes with the Securities and Exchange Commission in the future. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Syros expressly disclaims any obligation to
update any forward-looking statements, whether because of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170831005001/en/
Media Contact:
Syros Pharmaceuticals
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com
Source: Syros Pharmaceuticals
Released August 31, 2017